Abstract
Vagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavioral deficits in a rat model of depression. While the influences of VNS on monoamine metabolism and mood improvement are well-recognized, the underlying mechanisms mediating its antidepressive action remain poorly understood. Recent findings suggest that VNS-enhanced proliferation of hippocampal neural progenitor cells (NPCs) and synaptic transmission might serve as a monoamine-independent pathway contributive to the beneficial effects of VNS on depression. Here we briefly reviewed the recent progress in this field, based on which we propose that there might be, at least, two little-overlapped, and yet interactive pathways mediating the antidepressive action of VNS.
Keywords: Vagus nerve stimulation, depression, neurogenesis, hippocampus, monoamine, brain-derived neurotrophic factor.
Current Molecular Medicine
Title:Vagus nerve stimulation in treating depression: A tale of two stories.
Volume: 16 Issue: 1
Author(s): T.-F. Yuan, A. Li, X. Sun, O. Arias-Carrión and S. Machado
Affiliation:
Keywords: Vagus nerve stimulation, depression, neurogenesis, hippocampus, monoamine, brain-derived neurotrophic factor.
Abstract: Vagus nerve stimulation (VNS) has been widely used to treat different neurological disorders, especially epilepsy. Accumulating evidence also suggests its potential application in antidepressive therapy, given that VNS has been confirmed by several clinical trials to exert long-term effects on mitigating depression and reducing the risk of relapse in depressed patients. Likewise, VNS has also proven to ameliorate the behavioral deficits in a rat model of depression. While the influences of VNS on monoamine metabolism and mood improvement are well-recognized, the underlying mechanisms mediating its antidepressive action remain poorly understood. Recent findings suggest that VNS-enhanced proliferation of hippocampal neural progenitor cells (NPCs) and synaptic transmission might serve as a monoamine-independent pathway contributive to the beneficial effects of VNS on depression. Here we briefly reviewed the recent progress in this field, based on which we propose that there might be, at least, two little-overlapped, and yet interactive pathways mediating the antidepressive action of VNS.
Export Options
About this article
Cite this article as:
Yuan T.-F., Li A., Sun X., Arias-Carrión O. and Machado S., Vagus nerve stimulation in treating depression: A tale of two stories., Current Molecular Medicine 2016; 16 (1) . https://dx.doi.org/10.2174/1566524016666151222143609
DOI https://dx.doi.org/10.2174/1566524016666151222143609 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dietary and Plant Polyphenols Exert Neuroprotective Effects and Improve Cognitive Function in Cerebral Ischemia
Recent Patents on Food, Nutrition & Agriculture Hallucinations Associated with Topiramate Therapy: A Case Report and Review of the Literature
Current Drug Safety Exosomes: Natural Carriers for siRNA Delivery
Current Pharmaceutical Design Exploring the Role of “Brahmi” (Bacopa monnieri and Centella asiatica) in Brain Function and Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Recent Software Developments and Applications in Functional Imaging
Current Pharmaceutical Biotechnology Liver-Brain Axis in Sporadic Alzheimer’s Disease: Role of Ten Signature Genes in a Mouse Model
CNS & Neurological Disorders - Drug Targets Clinical Features of Scleroderma-Like Disorders: A Challenge for the Rheumatologist
Current Rheumatology Reviews Assessment of Memory Impairment in Early Diagnosis of Alzheimer’s Disease
Current Alzheimer Research MicroRNAs in CAG Trinucleotide Repeat Expansion Disorders: an Integrated Review of the Literature
CNS & Neurological Disorders - Drug Targets The Use of Antiepileptic Drugs in Paediatric Neurosurgical Conditions
Current Pharmaceutical Design University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology
Current Alzheimer Research Ion Channel Modulation as a Therapeutic Approach in Multiple Sclerosis
Current Medicinal Chemistry Neuropharmacology of Vestibular System Disorders
Current Neuropharmacology Plasma Phospholipids are Associated with Mild Cognitive Impairment in Type 2 Diabetic Patients
Current Alzheimer Research New Insights into Pre-, Intra- and Post-Operative Brain Mapping in Low- Grade Glioma Surgery: Towards a Longitudinal Study of Cerebral Plasticity
Current Medical Imaging The Importance of Bioactivation in Computer-Guided Drug Repositioning. Why the Parent Drug is Not Always Enough
Current Topics in Medicinal Chemistry FMRI in Pediatric Neurodevelopmental Disorders
Current Pediatric Reviews Functional Characterisation of Homomeric Ionotropic Glutamate Receptors GluR1-GluR6 in a Fluorescence-Based High Throughput Screening Assay
Combinatorial Chemistry & High Throughput Screening Expanding Spectrum of Sodium Potassium Chloride Co-transporters in the Pathophysiology of Diseases
Current Neuropharmacology PET with Non-Standard Nuclides
Current Topics in Medicinal Chemistry